Tag: acromegaly market forecast

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Acromegaly Market Size Changed, over the years?

The expansion of the acromegaly market has been swift in the past few years. The expectation is that it will escalate from $2.15 billion in 2024 to $2.57 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 19.6%. The growth experienced during the historic period can be accredited to factors such as a rise in the prevalence of acromegaly therapeutics, increased acromegaly awareness, government initiatives, and the demand for efficient treatments.

How Much Will the Acromegaly Market Be Worth in 2029?

In the upcoming years, a swift expansion is predicted for the acromegaly industry, with market size potentially amassing $4.92 billion by 2029 at a compound annual growth rate (CAGR) of 17.6%. This progression in the forecast period might be due to higher investment in the research and development of acromegaly treatments, increased frequency of screening programs, growing healthcare expenditure, and a surge in preference for minimally invasive treatment alternatives. The forecast period is marked by emerging trends such as groundbreaking treatments for acromegaly, the evolution of targeted therapies specifically for acromegaly, a robust drug pipeline, enhancements in treatment choices, and sophisticated personalized medicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Which is the Largest Company in the Acromegaly Market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

What Are the Main Market Drivers in the Acromegaly Industry?

The continued rise in hormonal disorders like diabetes is poised to boost the acromegaly market’s growth. Referred to medically as endocrine disorders, these diseases result from malfunctions within the endocrine system, with diabetes being a significant and common hormonal disease. Both acromegaly and other endocrine disorders can stem from excessive hormone production, such as growth hormone or cortisol. What’s more, high levels of growth hormone can affect insulin synthesis, leading around half of those with acromegaly to develop insulin resistance or type 2 diabetes mellitus. For example, the Office for Health Improvement and Disparities, a UK government department, reported in March 2024 that from March 2022 to March 2023, there was a 22% increase in individuals with type 1 diabetes receiving all eight recommended care processes, a 21% increase for type 2 diabetes, and a peak of 37.9% achieving target HbA1c levels as per the National Diabetes Audit (NDA). Hence, the surge in hormonal diseases is fuelling the growth of the acromegaly market.

Acromegaly Market Driver: The Influence of Genetic Abnormalities on The Growth of The Acromegaly Market

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

How Is the Acromegaly Market Segments Structured?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

What Strategic Trends Are Transforming the Acromegaly Market?

Key players in the acromegaly market are concentrating on creating innovative products and solutions, like generic lanreotide, to augment treatment choices and better patient results. Generic lanreotide is an unbranded version of the medication used for managing acromegaly and certain neuroendocrine tumors, functioning as a somatostatin analogue that minimizes growth hormone secretion and enhances patient access to effective treatments. For instance, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical firm with a focus on generic drugs, introduced the one and only generic version of Sandostatin LAR Depot in the United States. The injected suspension, octreotide acetate, is used to manage acromegaly and severe diarrhea related to carcinoid syndrome. This product’s introduction increases the availability of essential treatment for patients needing such therapies.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Global Regions Offer the Highest Growth in the Acromegaly Market?

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913

This Report Delivers Insight On:

1. How big is the acromegaly market, and how is it changing globally?

2. Who are the major companies in the acromegaly market, and how are they performing?

3. What are the key opportunities and risks in the acromegaly market right now?

4. Which products or customer segments are growing the most in the acromegaly market?

5. What factors are helping or slowing down the growth of the acromegaly market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the acromegaly industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Projected Market Size and Growth Rates for the Acromegaly Market From 2025 To 2029?

In the past few years, the acromegaly market has seen swift expansion. This market, which is projected to increase from $2.15 billion in 2024 to $2.57 billion in 2025, will rise at a CAGR of 19.6%. The historic market expansion can be connected to factors such as the growing incidence of acromegaly therapeutics, heightened acromegaly awareness, government actions, and the demand for potent treatments.

The market size for acromegaly is anticipated to experience swift expansion in the ensuing years. The projected growth brings the worth to approximately $4.92 billion in 2029, with a CAGR of 17.6%. Towards this progression in the forecast period, factors attributed include increased investment in research and development for acromegaly cures, the growth in the number of screening initiatives, escalated spending on healthcare, and a mounting demand for low-risk treatment alternatives. The forecast period also foresees major trends such as the invention of unique treatments for acromegaly, the creation of specific therapies for the disorder, a robust drug pipeline, enhancements in treatment choices, and advances in personalized medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Which Primay Drivers Are Accelerating Growth in the Acromegaly Market?

The escalating prevalence of endocrine diseases like diabetes is anticipated to fuel the acromegaly market’s expansion. Endocrine disorders, essentially medical conditions resulting from an impaired endocrine system, are also classified as hormonal diseases. Diabetes ranks high within these diseases. Overproduction of certain hormones, like growth hormone or cortisol, could give rise to Acromegaly and other endocrine disorders. Furthermore, the overabundance of growth hormone might influence insulin synthesis, resulting in around 50% of acromegaly patients developing insulin resistance or Type-2 diabetes mellitus. To illustrate, information released by the UK’s Office for Health Improvement and Disparities in March 2024 revealed a substantial rise in the percentage of individuals receiving all eight suggested care procedures for type 1 and type 2 diabetes between March 2022 and 2023 (22% and 21% respectively), and an increased percentage (37.9%) of individuals reaching the target HbA1c levels, the highest figure ever reported by the National Diabetes Audit (NDA). Consequently, the rising cases of hormonal diseases are promoting the acromegaly market’s expansion. Another key driver for the acromegaly market’s growth is the surging instances of genetic abnormalities. Genetic aberrations, typically known as genetic defects, can lead to altered features, functions, or characteristics owing to changes in the DNA sequence within genes. Acromegaly often arises due to an overproduction of growth hormone by the pituitary gland, frequently stemming from benign adenomas, which can occur abruptly or be associated with specific genetic irregularities. As per data from the World Health Organization in February 2022, birth abnormalities cause the deaths of 240,000 newborns within their first 28 days of life each year, with an additional 170,000 casualties among 1-month to 5-year old children due to birth defects such as heart issues, neural tube defects, and Down syndrome. Therefore, the escalating prevalence of genetic defects is also bolstering the acromegaly market.

Which Primary Segments of the Acromegaly Market Are Driving Growth and Industry Transformations?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Which Regions Are Key Players in the Growth of the Acromegaly Market?

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Acromegaly Industry Dynamics?

Major players in the acromegaly market are concentrating their efforts on creating cutting-edge products and solutions, such as generic lanreotide, to boost the range of treatments available and improve patient health outcomes. Generic lanreotide is simply an unbranded version of the medication used for treating acromegaly and some neuroendocrine tumors. It functions as a somatostatin analogue, diminishing growth hormone secretion and making effective treatment options more accessible for patients. For instance, Teva Pharmaceutical Industries Ltd., a company based in Israel and focused on generic drugs, rolled out the first and only generic version of Sandostatin LAR Depot in the United States in October 2024. The injectable suspension, known as octreotide acetate, is prescribed for treating acromegaly and severe diarrhea caused by carcinoid syndrome. This launch improves access to essential therapy for patients who need these treatments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

What Parameters Are Used to Define the Acromegaly Market?

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland, a small gland located at the base of the brain, produces excessive growth hormone. This excess growth hormone leads to the enlargement and thickening of bones and tissues in various body parts, particularly the hands, feet and face.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theAcromegaly Market?

The escalating rise in hormonal disorders such as diabetes is predicted to fuel the expansion of the acromegaly market in the future. Hormonal disorders, also termed endocrine disorders, are diseases arising from disfunction in the endocrine system. With diabetes being one of the most common and prominent hormonal disorders, acromegaly, along with other endocrine disorders, can be induced by an overproduction of certain hormones like growth hormone or cortisol. Moreover, around half of the individuals with acromegaly could develop insulin resistance or type 2 diabetes mellitus because of the influence of elevated levels of growth hormone on the synthesis of insulin. For example, as reported by the UK-based government department, the Office for Health Improvement and Disparities, in March 2024, from March 2022 to March 2023, the proportion of people with type 1 diabetes receiving all eight recommended care processes saw a surge of 22%, and a 21% rise for type 2 diabetes. Meanwhile, those attaining target HbA1c levels grew to 37.9% as per the National Diabetes Audit (NDA), marking the highest value ever recorded. Hence, the rising prevalence of hormonal disorders is fuelling the growth of the acromegaly market.

Acromegaly Market Driver: Influence of Genetic Abnormalities on Acromegaly Market Expansion

 

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

What is the Predicted Annual Growth Rate of theAcromegaly Market Impact Industry Trends by 2034?

In the last few years, the market size of acromegaly has seen substantial expansion. The market is projected to increase from a $2.15 billion valuation in 2024 to $2.57 billion in 2025, experiencing a compound annual growth rate (CAGR) of 19.6%. This upsurge during the historic period can be tied to factors such as increased incidence of acromegaly therapeutics, heightened acromegaly awareness, governmental efforts, and the need for efficient treatments.

The market size of acromegaly is predicted to witness a swift expansion in the coming years. The market is anticipated to surge to $4.92 billion by 2029, growing at a compound annual growth rate (CAGR) of 17.6%. The increased growth in the projection period can be ascribed to the inflow of resources into research and development efforts for acromegaly cures, an upswing in the number of screening schemes, escalating healthcare expenditure, and a burgeoning demand for less invasive treatment alternatives. Key trends projected for the forecast period include groundbreaking acromegaly treatments, the formation of acromegaly targeted therapies, a robust pipeline of pharmaceuticals, progressions in treatment choices, and sophisticated personalized medicine.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913

What Are the Latest Innovations Influencing theAcromegaly Market?

Key players in the acromegaly market are investing in the creation of cutting-edge products and services, such as generic lanreotide, to augment the treatment landscape and augment patient results. Generic lanreotide is essentially a non-branded version of the drug used to treat acromegaly and certain neuroendocrine tumours. It serves as a somatostatin analogue, lowering the secretion of growth hormone and thereby expanding patient access to efficient treatment alternatives. For example, in October 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical firm with a focus on generic medications, introduced the inaugural and sole generic variant of Sandostatin LAR Depot in the United States. The injection suspension, known as octreotide acetate, is recommended for the treatment of acromegaly and severe diarrhoea related to carcinoid syndrome. This product launch broadens the reach of vital treatment for patients in need of these therapies.

Who Are the Major Industry Players Accelerating Growth in theAcromegaly Market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

Which Primary Segments of the Acromegaly Market Are Driving Growth and Industry Transformations?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12913&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theAcromegaly Market?# Market?

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Acromegaly Market 2025, By The Business Research Company:

Nerve Repair And Regenerative Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Neurophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurophysiology-devices-and-equipment-global-market-report

Generic Central Nervous System Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the acromegaly market?

In recent years, the size of the acromegaly market has expanded significantly. It is projected to rise from $2.15 billion in 2024 to $2.57 billion in 2025, with a compound annual growth rate (CAGR) of 19.6%. The growth during the historic period is due to factors such as the increased prevalence of acromegaly treatments, heightened awareness about acromegaly, government-led initiatives, and the demand for effective treatments.

What will be the active cosmetics market size in the future?

In the upcoming years, rapid expansion is anticipated in the acromegaly market, with a forecasted size of $4.92 billion in 2029, growing at a compound annual growth rate (CAGR) of 17.6%. Factors contributing to this growth throughout the forecasted period include amplified investment in acromegaly treatment research and development, increased screening initiatives, amplified healthcare expenditure, and a rising demand for less invasive treatment methods. The forecast period also expects to witness specific trends, including innovations in acromegaly treatments, the evolution of targeted therapies for acromegaly, a robust drug pipeline, advancements in treatment alternatives, and progress in personalized medicine.

Get your acromegaly market report here!

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

What main drivers are fueling expansion in the acromegaly market?

An escalating incidence of hormonal diseases like diabetes is anticipated to fuel the acromegaly market’s growth. Endocrine disorders or hormonal diseases are health conditions emerging from the malfunctioning of the endocrine system. Diabetes stands as one of the most common and significant among these diseases. Overproduction of particular hormones, including growth hormone or cortisol, can result in acromegaly and other endocrine diseases. Furthermore, around 50% of acromegaly patients may develop insulin resistance or type 2 diabetes mellitus, given the influence of high levels of growth hormone on insulin production. For instance, the Office for Health Improvement and Disparities, a UK government department, reported in March 2024 that between March 2022 and March 2023, there was a 22% rise in the percentage of type 1 diabetic individuals receiving all eight suggested care processes, and a 21% increase for type 2 diabetes. Additionally, the percentage reaching target HbA1c levels increased to 37.9%, the maximum ever reported by the National Diabetes Audit (NDA). Consequently, the rising incidence of hormonal diseases propels the expansion of the acromegaly market.

Acromegaly Market Driver: The Effect of Genetic Abnormalities on the Growth of the Acromegaly Market

 

What key areas define the segmentation of the global acromegaly market?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Who are the dominant players expanding their reach in the acromegaly market?

Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.

How are evolving market trends shaping acromegaly Strategies?

Notable businesses in the acromegaly market are concentrating their efforts on the creation of novel products and solutions, including generic lanreotide, to augment treatment choices and enhance patient results. Generic lanreotide is essentially a non-branded version of a medication utilized in the treatment of acromegaly and specific neuroendocrine tumors, functioning as a somatostatin analogue that reduces the secretion of growth hormone, thus expanding patient access to effective treatments. To illustrate, Teva Pharmaceutical Industries Ltd., a firm based in Israel with a focus on generic drugs, introduced the first and exclusive generic version of Sandostatin LAR Depot in the United States in October 2024. The drug, octreotide acetate, is designed to treat acromegaly and severe diarrhoea related to carcinoid syndrome in injectable suspension form. This new addition widens the access to vital therapy for patients in need of these treatments.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913

Which regions are emerging as leaders in the acromegaly market?

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Nerve Repair And Regenerative Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Neurophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurophysiology-devices-and-equipment-global-market-report

Generic Central Nervous System Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Significant is the Anticipated Growth Rate of the Acromegaly Market from 2025 to 2034?

The market for acromegaly has seen swift expansion in recent years. There is an expected increase from $2.15 billion in 2024 to $2.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 19.6%. Factors such as the rising prevalence of therapeutic treatments for acromegaly, increased awareness of the condition, government initiatives, and the demand for efficacious treatments have contributed to the growth during the historic period.

There is an anticipation for the market size of acromegaly to witness considerable growth over the upcoming years, reaching a value of $4.92 billion in 2029 with a 17.6% compound annual growth rate (CAGR). This expansion forecasted over the period can be credited to investment in research and development programs for acromegaly treatments, heightened screening initiatives, increased healthcare expenditure, and a growing preference for less intrusive treatment choices. Top trends for the anticipated period involve novel acromegaly treatments, introduction of specifically targeted therapies, a robust pipeline of medicinal drugs, advances in treatment strategies, and enhanced tailor-made medicine.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the acromegaly Market?

An increase in hormonal diseases such as diabetes is projected to fuel the acromegaly market’s growth. Known as endocrine disorders, hormonal diseases are health conditions caused by abnormalities in the endocrine system. Diabetes is a prominent hormonal disease. Overproduction of certain hormones, such as growth hormone or cortisol, can lead to acromegaly and other endocrine disorders. Furthermore, excessive growth hormone may compromise insulin synthesis, leading to insulin resistance or type-2 diabetes in approximately 50% of acromegaly patients. The Office for Health Improvement and Disparities reported in March 2024 that from March 2022 to March 2023, the number of type 1 diabetes patients receiving all eight recommended care processes rose by 22%, and the number for type 2 diabetes increased by 21%. During that time, the number of patients achieving target HbA1c levels jumped to 37.9%, the National Diabetes Audit’s highest-ever figure. Therefore, the rise in hormonal disease prevalence is stimulating the acromegaly market growth. The acromegaly market is expected to expand due to the increasing prevalence of genetic abnormalities. These abnormalities, also called genetic defects or disorders, are changes in a person’s genetic code that can lead to unusual characteristics or functions. Overproduction of growth hormone by the pituitary gland, often caused by benign adenomas, can cause acromegaly. These adenomas can occur randomly or be associated with specific genetic conditions. For instance, in February 2022, the World Health Organization stated that birth abnormalities cause 240,000 newborns to die within the first 28 days of life each year and another 170,000 children between 1 month and 5 years old die due to anomalies including heart defects, neural tube defects, and Down syndrome. Thus, the increased prevalence of genetic abnormalities is expected to fuel the acromegaly market’s growth.

Request Your Free Acromegaly Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp

Who Are the Dominant Players Pushing the Boundaries of the Acromegaly Market?

Major companies operating in the acromegaly market are:

• Pfizer Inc._x000D_

• Johnson & Johnson Private Limited_x000D_

• Merck & Co Inc._x000D_

• AbbVie Inc._x000D_

• Bayer AG_x000D_

How Are Market Trends Revolutionizing the Acromegaly Industry in Recent Times?

Leading firms in the acromegaly market are striving to create innovative products and solutions, like generic lanreotide, to advance treatment alternatives and ameliorate patient outcomes. Generic lanreotide is a non-branded version of the drug used for the treatment of acromegaly and specific neuroendocrine tumors. It functions as a somatostatin analog, reducing the secretion of growth hormones and enhancing patient access to effective therapy options. For example, in October 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical firm from Israel that specializes in generic drugs, introduced the first and exclusive generic edition of the Sandostatin LAR Depot in the United States. The injectable compound, octreotide acetate, is prescribed for acromegaly treatment and severe diarrhoea related to carcinoid syndrome. This new addition makes crucial therapy more accessible for patients necessitating these treatments.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report

What Are the Core Categories and Segments in the Acromegaly Market Driving Demand and Growth?

The acromegaly market covered in this report is segmented –

1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone

2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments

5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly

2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess

Which Geographic Areas Are Influencing the Growth of the Acromegaly Market?

North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Core Features That Define the Acromegaly Market?

Acromegaly is a rare hormonal disorder that occurs when the pituitary gland, a small gland located at the base of the brain, produces excessive growth hormone. This excess growth hormone leads to the enlargement and thickening of bones and tissues in various body parts, particularly the hands, feet and face.

Browse Through More Similar Reports By The Business Research Company:

Nerve Repair And Regenerative Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Neurophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurophysiology-devices-and-equipment-global-market-report

Generic Central Nervous System Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: